Moreover, the FLAURA study demonstrated that osimertinib was more effective in improving PFS as a first-line treatment for EGFR mutation-positive advanced NSCLC compared to standard EGFR-TKIs (gefitinib or erlotinib) with a similar safety profile and lower rates of serious adverse events [100]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.